Effects of atorvastatin in suppressing pulmonary vascular remodeling in rats with chronic obstructive pulmonary disease

[1]  M. Miravitlles,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. , 2020, Archivos de bronconeumologia.

[2]  P. He,et al.  The effect of statins and the synthetic LXR agonist T0901317 on expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro , 2019, Pharmacological reports : PR.

[3]  Feng Xu,et al.  HDAC2 attenuates airway inflammation by suppressing IL-17A production in HDM-challenged mice. , 2019, American journal of physiology. Lung cellular and molecular physiology.

[4]  S. Hosseinimehr,et al.  Atorvastatin mitigates cyclophosphamide-induced hepatotoxicity via suppression of oxidative stress and apoptosis in rat model , 2018, Research in pharmaceutical sciences.

[5]  Min Zhang,et al.  Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response , 2018, Molecules.

[6]  D. Perrea,et al.  Protective effects of N-acetylcystein and atorvastatin against renal and hepatic injury in a rat model of intestinal ischemia-reperfusion. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  Nirmal Singh,et al.  Histone acetylation and histone deacetylation in neuropathic pain: An unresolved puzzle? , 2017, European journal of pharmacology.

[8]  N. Hansel,et al.  Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management , 2015, Seminars in Respiratory and Critical Care Medicine.

[9]  K. Miller,et al.  Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. , 2013, Mutation research.

[10]  S. Lim.  Role of Statins in Coronary Artery Disease , 2013, Chonnam medical journal.

[11]  Wei-wei Su,et al.  Characteristic comparison of three rat models induced by cigarette smoke or combined with LPS: to establish a suitable model for study of airway mucus hypersecretion in chronic obstructive pulmonary disease. , 2012, Pulmonary pharmacology & therapeutics.

[12]  Jung Weon Lee,et al.  Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinic–polycytidylic acid-induced pneumonia , 2012, European Respiratory Journal.

[13]  Yan Zhou,et al.  Erythromycin ameliorates cigarette-smoke-induced emphysema and inflammation in rats. , 2012, Translational research : the journal of laboratory and clinical medicine.

[14]  R. Hopkins,et al.  Pharmacological actions of statins: potential utility in COPD , 2009, European Respiratory Review.

[15]  P. J. Barnes,et al.  Systemic manifestations and comorbidities of COPD , 2009, European Respiratory Journal.

[16]  P. Barnes,et al.  Role of HDAC2 in the pathophysiology of COPD. , 2009, Annual review of physiology.

[17]  J. Lordan,et al.  Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[18]  S. Kourembanas,et al.  Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. , 1998, American journal of respiratory cell and molecular biology.

[19]  S. Archer,et al.  Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia. , 1996, Circulation research.

[20]  G. Walsh.  Defective apoptotic cell clearance in asthma and COPD--a new drug target for statins? , 2008, TIPS - Trends in Pharmacological Sciences.

[21]  U. Laufs,et al.  Pleiotropic effects of statins. , 2005, Annual review of pharmacology and toxicology.

[22]  G. Bouvenot,et al.  Les statines : nouvelles propriétés , 2003 .